← Back to Clinical Trials
Recruiting NCT05784740

NCT05784740 Precision Exercise to Improve Outcomes in Sepsis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05784740
Status Recruiting
Phase
Sponsor University of British Columbia
Condition Sepsis
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2023-04-17
Primary Completion 2025-03

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
12-week precision exercise training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2023-04-17 with a primary completion date of 2025-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this interventional clinical research study is to assess the efficacy of a 12-week precision exercise training intervention to improve exercise tolerance in sepsis survivors. The main question it aims to answer is does a 12-week precision exercise training program improve constant load exercise time in sepsis survivors? Participants will: * Answer questionnaires related to patient reported outcomes and give a blood sample * Perform a constant load exercise test * Complete 12-weeks (3 x per week, 36 session in total) of precision exercise training consisting of individualized, nonlinear periodized strength and aerobic exercise training. Researchers will compare the exercise group to an attention control group of sepsis survivors who do not receive exercise training but instead undergo usual care procedures and receive general lifestyle advice 1x per week.

Eligibility Criteria

Inclusion Criteria: * Signed informed consent * At least 19 years of age * ≥60 days prior to study enrollment, known or suspected infection that includes at least two of the following clinical criteria that together constitute a new bedside clinical score termed quickSOFA (qSOFA): respiratory rate \>22breaths/min, altered mentation, or systolic blood pressure \<100mmHg. * Cardiorespiratory fitness \<80% of age and sex-predicted norms * Can commit to attending 3 exercise sessions a week for 12-weeks Exclusion Criteria: * Unable to provide informed consent * On supplemental oxygen * Known previous cardiac or cerebral vascular events in the past 90 days * Diabetes * Autoimmune diseases or on daily immunomodulatory drugs * Obstructive sleep apnea * Uncontrolled hypertension * Known pregnancy/ intending to get pregnant within 28 days of enrolling in the study or breastfeeding * Desaturation during exercise SpO2\<85% * Cardiovascular contraindication or musculoskeletal limitations to exercise as assessed during the cardiopulmonary exercise test

Contact & Investigator

Central Contact

Graeme Koelwyn, PhD

✉ graeme.koelwyn@hli.ubc.ca

📞 604-682-2344

Principal Investigator

Graeme Koelwyn, PhD

PRINCIPAL INVESTIGATOR

University of British Columbia

Frequently Asked Questions

Who can join the NCT05784740 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05784740 currently recruiting?

Yes, NCT05784740 is actively recruiting participants. Contact the research team at graeme.koelwyn@hli.ubc.ca for enrollment information.

Where is the NCT05784740 trial being conducted?

This trial is being conducted at Vancouver, Canada.

Who is sponsoring the NCT05784740 clinical trial?

NCT05784740 is sponsored by University of British Columbia. The principal investigator is Graeme Koelwyn, PhD at University of British Columbia. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology